Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium.

DiNorcia J, Florman SS, Haydel B, Tabrizian P, Ruiz RM, Klintmalm GB, Senguttuvan S, Lee DD, Taner CB, Verna EC, Halazun KJ, Hoteit M, Levine MH, Chapman WC, Vachharajani N, Aucejo F, Nguyen MH, Melcher ML, Tevar AD, Humar A, Mobley C, Ghobrial M, Nydam TL, Amundsen B, Markmann JF, Berumen J, Hemming AW, Langnas AN, Carney CA, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Kueht ML, Jones CM, Fishbein TM, Markovic D, Busuttil RW, Agopian VG.

Ann Surg. 2019 Mar 5. doi: 10.1097/SLA.0000000000003253. [Epub ahead of print]

PMID:
30870180
2.

Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.

Agopian VG, Morshedi MM, McWilliams J, Harlander-Locke MP, Markovic D, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Hiatt JR, Busuttil RW.

Ann Surg. 2015 Sep;262(3):536-45; discussion 543-5. doi: 10.1097/SLA.0000000000001384.

PMID:
26258323
3.

Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.

Agopian VG, Harlander-Locke MP, Ruiz RM, Klintmalm GB, Senguttuvan S, Florman SS, Haydel B, Hoteit M, Levine MH, Lee DD, Taner CB, Verna EC, Halazun KJ, Abdelmessih R, Tevar AD, Humar A, Aucejo F, Chapman WC, Vachharajani N, Nguyen MH, Melcher ML, Nydam TL, Mobley C, Ghobrial RM, Amundsen B, Markmann JF, Langnas AN, Carney CA, Berumen J, Hemming AW, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Kueht ML, Jones CM, Fishbein TM, Busuttil RW.

Ann Surg. 2017 Sep;266(3):525-535. doi: 10.1097/SLA.0000000000002381.

PMID:
28654545
4.

Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies.

El-Gazzaz G, Sourianarayanane A, Menon KV, Sanabria J, Hashimoto K, Quintini C, Kelly D, Eghtesad B, Miller C, Fung J, Aucejo F.

Hepatobiliary Pancreat Dis Int. 2013 Feb;12(1):34-41.

PMID:
23392796
5.

Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.

Kim JM, Kwon CH, Joh JW, Choi MS, Lee JH, Koh KC, Paik SW, Kim GS, Kim SJ, Lee SK, Yoo BC.

Transplant Proc. 2012 Mar;44(2):403-8. doi: 10.1016/j.transproceed.2012.01.067.

PMID:
22410028
6.

Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5.

Macdonald B, Sewell JL, Harper AM, Roberts JP, Yao FY.

Clin Transplant. 2015 Jun;29(6):506-12. doi: 10.1111/ctr.12542. Epub 2015 Apr 28.

7.

Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.

Kulik L, Heimbach JK, Zaiem F, Almasri J, Prokop LJ, Wang Z, Murad MH, Mohammed K.

Hepatology. 2018 Jan;67(1):381-400. doi: 10.1002/hep.29485. Epub 2017 Nov 29. Review.

PMID:
28859222
8.

Predictors of intermediate-term survival with destination locoregional therapy of hepatocellular cancer in patients either ineligible or unwilling for liver transplantation.

Ramanathan M, Shroads M, Choi M, Wood D, Seetharam A.

J Gastrointest Oncol. 2017 Oct;8(5):885-889. doi: 10.21037/jgo.2017.07.05. Review.

9.

A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.

Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW.

J Am Coll Surg. 2015 Apr;220(4):416-27. doi: 10.1016/j.jamcollsurg.2014.12.025. Epub 2014 Dec 27.

PMID:
25690672
10.

Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.

Firl DJ, Kimura S, McVey J, Hashimoto K, Yeh H, Miller CM, Markmann JF, Sasaki K, Aucejo FN.

Hepatology. 2018 Oct;68(4):1448-1458. doi: 10.1002/hep.29907.

PMID:
29604231
11.

Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.

Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY.

JAMA Oncol. 2017 Apr 1;3(4):493-500. doi: 10.1001/jamaoncol.2016.5116.

12.

Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.

Agopian VG, Harlander-Locke MP, Markovic D, Zarrinpar A, Kaldas FM, Cheng EY, Yersiz H, Farmer DG, Hiatt JR, Busuttil RW.

JAMA Surg. 2017 Jan 1;152(1):55-64. doi: 10.1001/jamasurg.2016.3310.

13.
14.

The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation.

Lai Q, Vitale A, Iesari S, Finkenstedt A, Mennini G, Onali S, Hoppe-Lotichius M, Manzia TM, Nicolini D, Avolio AW, Mrzljak A, Kocman B, Agnes S, Vivarelli M, Tisone G, Otto G, Tsochatzis E, Rossi M, Viveiros A, Ciccarelli O, Cillo U, Lerut J; European Hepatocellular Cancer Liver Transplant Study Group.

Liver Transpl. 2019 Jul;25(7):1023-1033. doi: 10.1002/lt.25492.

PMID:
31087772
15.

Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.

Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY.

Liver Transpl. 2013 Dec;19(12):1343-53. doi: 10.1002/lt.23753.

16.

Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.

Gordic S, Corcuera-Solano I, Stueck A, Besa C, Argiriadi P, Guniganti P, King M, Kihira S, Babb J, Thung S, Taouli B.

J Hepatol. 2017 Dec;67(6):1213-1221. doi: 10.1016/j.jhep.2017.07.030. Epub 2017 Aug 18.

PMID:
28823713
17.

Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC.

Kornberg A, Witt U, Matevossian E, Küpper B, Assfalg V, Drzezga A, Hüser N, Wildgruber M, Friess H.

PLoS One. 2013;8(1):e53960. doi: 10.1371/journal.pone.0053960. Epub 2013 Jan 22.

18.

Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria.

Ciccarelli O, Lai Q, Goffette P, Finet P, De Reyck C, Roggen F, Sempoux C, Doffagne E, Reding R, Lerut J.

Transpl Int. 2012 Aug;25(8):867-75. doi: 10.1111/j.1432-2277.2012.01512.x. Epub 2012 Jun 20.

19.

Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.

Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY.

Liver Transpl. 2014 Aug;20(8):945-51. doi: 10.1002/lt.23904. Epub 2014 Jul 12.

20.

Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.

Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J, Merion RM.

Dig Dis Sci. 2012 Mar;57(3):806-12. doi: 10.1007/s10620-011-1910-9. Epub 2011 Sep 28.

Supplemental Content

Support Center